Literature DB >> 21596755

Intracellular storage and regulated secretion of von Willebrand factor in quantitative von Willebrand disease.

Jiong-Wei Wang1, Karine M Valentijn, Hetty C de Boer, Richard J Dirven, Anton Jan van Zonneveld, Abraham J Koster, Jan Voorberg, Pieter H Reitsma, Jeroen Eikenboom.   

Abstract

Several missense mutations in the von Willebrand Factor (VWF) gene of von Willebrand disease (VWD) patients have been shown to cause impaired constitutive secretion and intracellular retention of VWF. However, the effects of those mutations on the intracellular storage in Weibel-Palade bodies (WPBs) of endothelial cells and regulated secretion of VWF remain unknown. We demonstrate, by expression of quantitative VWF mutants in HEK293 cells, that four missense mutations in the D3 and CK-domain of VWF diminished the storage in pseudo-WPBs, and led to retention of VWF within the endoplasmic reticulum (ER). Immunofluorescence and electron microscopy data showed that the pseudo-WPBs formed by missense mutant C1060Y are indistinguishable from those formed by normal VWF. C1149R, C2739Y, and C2754W formed relatively few pseudo-WPBs, which were often short and sometimes round rather than cigar-shaped. The regulated secretion of VWF was impaired slightly for C1060Y but severely for C1149R, C2739Y, and C2754W. Upon co-transfection with wild-type VWF, both intracellular storage and regulated secretion of all mutants were (partly) corrected. In conclusion, defects in the intracellular storage and regulated secretion of VWF following ER retention may be a common mechanism underlying VWD with a quantitative deficiency of VWF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21596755      PMCID: PMC3129199          DOI: 10.1074/jbc.M110.215194

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Homozygous C2362F von Willebrand factor induces intracellular retention of mutant von Willebrand factor resulting in autosomal recessive severe von Willebrand disease.

Authors:  P Tjernberg; G Castaman; H L Vos; R M Bertina; J C J Eikenboom
Journal:  Br J Haematol       Date:  2006-05       Impact factor: 6.998

Review 2.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

Authors:  J E Sadler; U Budde; J C J Eikenboom; E J Favaloro; F G H Hill; L Holmberg; J Ingerslev; C A Lee; D Lillicrap; P M Mannucci; C Mazurier; D Meyer; W L Nichols; M Nishino; I R Peake; F Rodeghiero; R Schneppenheim; Z M Ruggeri; A Srivastava; R R Montgomery; A B Federici
Journal:  J Thromb Haemost       Date:  2006-08-02       Impact factor: 5.824

3.  Distribution of HLA class II molecules in epidermal Langerhans cells in situ.

Authors:  A M Mommaas; A A Mulder; C J Out; G Girolomoni; H K Koerten; B J Vermeer; F Koning
Journal:  Eur J Immunol       Date:  1995-02       Impact factor: 5.532

4.  Cysteine-mutations in von Willebrand factor associated with increased clearance.

Authors:  C J Schooten; P Tjernberg; E Westein; V Terraube; G Castaman; J A Mourik; M J Hollestelle; H L Vos; R M Bertina; H M Berg; J C J Eikenboom; P J Lenting; C V Denis
Journal:  J Thromb Haemost       Date:  2005-10       Impact factor: 5.824

5.  Mutations C1157F and C1234W of von Willebrand factor cause intracellular retention with defective multimerization and secretion.

Authors:  A Hommais; A Stépanian; E Fressinaud; C Mazurier; D Meyer; J P Girma; A S Ribba
Journal:  J Thromb Haemost       Date:  2006-01       Impact factor: 5.824

6.  Characterization of the von Willebrand factor gene (VWF) in von Willebrand disease type III patients from 24 families of Swedish and Finnish origin.

Authors:  Z P Zhang; M Blombäck; N Egberg; G Falk; M Anvret
Journal:  Genomics       Date:  1994-05-01       Impact factor: 5.736

Review 7.  Biochemistry and genetics of von Willebrand factor.

Authors:  J E Sadler
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

8.  The physiological function of von Willebrand's factor depends on its tubular storage in endothelial Weibel-Palade bodies.

Authors:  Grégoire Michaux; Kate B Abbitt; Lucy M Collinson; Sandra L Haberichter; Keith E Norman; Daniel F Cutler
Journal:  Dev Cell       Date:  2006-02       Impact factor: 12.270

9.  An AP-1/clathrin coat plays a novel and essential role in forming the Weibel-Palade bodies of endothelial cells.

Authors:  Winnie W Y Lui-Roberts; Lucy M Collinson; Lindsay J Hewlett; Grégoire Michaux; Daniel F Cutler
Journal:  J Cell Biol       Date:  2005-08-08       Impact factor: 10.539

10.  A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function.

Authors:  Alessandra Casonato; Maria Grazia Cattini; Carmen Soldera; Stefania Marcato; Francesca Sartorello; Elena Pontara; Antonio Pagnan
Journal:  J Lab Clin Med       Date:  2004-11
View more
  16 in total

1.  Enhanced assay of endothelial exocytosis using extracellular matrix components.

Authors:  Michael B LoMonaco; Charles J Lowenstein
Journal:  Anal Biochem       Date:  2014-02-20       Impact factor: 3.365

Review 2.  Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science.

Authors:  Soundarya Selvam; Paula James
Journal:  Semin Thromb Hemost       Date:  2017-05-05       Impact factor: 4.180

3.  Biogenesis of Weibel-Palade bodies in von Willebrand's disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formation.

Authors:  Jiong-Wei Wang; Dafna J Groeneveld; Guy Cosemans; Richard J Dirven; Karine M Valentijn; Jan Voorberg; Pieter H Reitsma; Jeroen Eikenboom
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

4.  Mutations in the D'D3 region of VWF traditionally associated with type 1 VWD lead to quantitative and qualitative deficiencies of VWF.

Authors:  Tara C White-Adams; Christopher J Ng; Paula M Jacobi; Sandra L Haberichter; Jorge A Di Paola
Journal:  Thromb Res       Date:  2016-08-10       Impact factor: 3.944

5.  Discrepant platelet and plasma von Willebrand factor in von Willebrand disease patients with p.Pro2808Leufs*24.

Authors:  M L Bowman; F G Pluthero; A Tuttle; L Casey; L Li; H Christensen; K S Robinson; D Lillicrap; W H A Kahr; P James
Journal:  J Thromb Haemost       Date:  2017-06-06       Impact factor: 5.824

6.  Insights into pathological mechanisms of missense mutations in C-terminal domains of von Willebrand factor causing qualitative or quantitative von Willebrand disease.

Authors:  Hamideh Yadegari; Julia Driesen; Anna Pavlova; Arijit Biswas; Vytautas Ivaskevicius; Robert Klamroth; Johannes Oldenburg
Journal:  Haematologica       Date:  2013-03-28       Impact factor: 9.941

7.  Blocking von Willebrand factor for treatment of cutaneous inflammation.

Authors:  Carina Hillgruber; Annika K Steingräber; Birgit Pöppelmann; Cécile V Denis; Jerry Ware; Dietmar Vestweber; Bernhard Nieswandt; Stefan W Schneider; Tobias Goerge
Journal:  J Invest Dermatol       Date:  2013-06-28       Impact factor: 8.551

8.  Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A.

Authors:  Stefanie D Roth; Jörg Schüttrumpf; Peter Milanov; Daniela Abriss; Christopher Ungerer; Patricia Quade-Lyssy; Jeremy C Simpson; Rainer Pepperkok; Erhard Seifried; Torsten Tonn
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

9.  Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells.

Authors:  Richard D Starke; Koralia E Paschalaki; Clare E F Dyer; Kimberly J Harrison-Lavoie; Jacqueline A Cutler; Thomas A J McKinnon; Carolyn M Millar; Daniel F Cutler; Mike A Laffan; Anna M Randi
Journal:  Blood       Date:  2013-01-25       Impact factor: 22.113

10.  Characterization of zebrafish von Willebrand factor reveals conservation of domain structure, multimerization, and intracellular storage.

Authors:  Arunima Ghosh; Andy Vo; Beverly K Twiss; Colin A Kretz; Mary A Jozwiak; Robert R Montgomery; Jordan A Shavit
Journal:  Adv Hematol       Date:  2012-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.